The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?
Journal article, 2011

ABSTRACT: BACKGROUND: A substantial prevalence of mild neurocognitive disorders has been reported in HIV, also in patients treated with combination antiretroviral therapy (cART). This includes a new disorder that has been termed asymptomatic neurocognitive impairment (ANI). DISCUSSION: ANI is identified by performance on formal neuropsychological testing that is at least 1 SD below the mean of normative scores in at least two cognitive domains out of at least five examined in patients without associated symptoms or evident functional impairment in daily living. While two tests are recommended to assess each domain, only one is required to fulfill this diagnostic criterion. Unfortunately, this definition necessitates that about 20 % of the cognitively normal HIV-infected population is classified as suffering ANI. This liberal definition raises important ethical concerns and has as well diagnostic and therapeutic implications. Since neither its biological substrate, prognostic significance nor therapeutic implications are clearly established, we recommend that this diagnosis be modified or applied cautiously. SUMMARY: The diagnoses of less severe forms of neurocognitive disorders in HIV relies on the outcomes of neuropsychological testing, and a high proportion of HIV-infected patients with effective cART may be classified as neurocognitively abnormal using the current criteria. The definition of ANI is not stringent, and results in approximately 20 % of the population being classified as abnormal. To us this seems an unacceptable false-positive rate.

Author

Magnus Gisslén

University of Gothenburg

R.W. Price

University of California

Staffan Nilsson

Chalmers, Mathematical Sciences, Mathematical Statistics

University of Gothenburg

BMC Infectious Diseases

14712334 (eISSN)

Vol. 11 1 Art nr. 356- 356

Subject Categories

Microbiology in the medical area

DOI

10.1186/1471-2334-11-356

PubMed

22204557

More information

Latest update

2/28/2018